Omeros (OMER) vs Seaport Therapeutics (SPTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Omeros is the larger company by market cap ($983.7 million vs $966.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | OMER | SPTX |
|---|---|---|
| Share price | $13.21 | $18.05 |
| Market cap | $983.66M | $966.23M |
| 1-day change | -5.71% | -1.47% |
| YTD return | -23.11% | — |
| 1-year return | +48.93% | — |
| 5-year return | +77.79% | — |
| P/E ratio (TTM) | 15.92 | — |
| Forward P/E | 11.95 | — |
| EPS (TTM) | $0.83 | $-4.35 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-3.35M | — |
| 52-week high | $21.24 | $28.38 |
| 52-week low | $6.70 | $14.85 |
| Distance from 52-week high | -37.81% | -36.40% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +108.18% | +105.71% |
| Average volume | 1.36M | 259.83K |
| Shares outstanding | 74.46M | 53.53M |
| Employees | 175 | 59 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Omeros
OMER stock →Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome.
Health Care · Biotechnology: Pharmaceutical Preparations · 175 employees
About Seaport Therapeutics
SPTX stock →Seaport Therapeutics, Inc., a clinical-stage therapeutics company, focuses on inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. It is leveraging its proprietary Glyph platform to advance a pipeline of therapies to address the unmet needs in depression and anxiety.
Health Care · Biotechnology: Pharmaceutical Preparations · 59 employees
OMER vs SPTX FAQ
Which is bigger, Omeros or Seaport Therapeutics?
Omeros (OMER) is larger, with a market capitalization of $983.66M compared with $966.23M for Seaport Therapeutics (SPTX).
Are Omeros and Seaport Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.